Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents

Journal of Psychopharmacology - Tập 14 Số 2 - Trang 114-138 - 2000
Mark J. Millan1, Françoise Lejeune, Alain P. Gobert2
1Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France
2Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, Croissy-sur-Seine, France

Tóm tắt

The frontal cortex (FCX) plays a key role in processes that control mood, cognition and motor behaviour, functions which are compromised in depression, schizophrenia and other psychiatric disorders. In this regard, there is considerable evidence that a perturbation of monoaminergic input to the FCX is involved in the pathogenesis of these states. Correspondingly, the modulation of monoaminergic transmission in the FCX and other corticolimbic structures plays an important role in the actions of antipsychotic and antidepressant agents. In order to further understand the significance of monoaminergic systems in psychiatric disorders and their treatment, it is essential to characterize mechanisms underlying their modulation. Within this framework, the present commentary focuses on our electrophysiological and dialysis analyses of the complex and reciprocal pattern of autoand heteroreceptor mediated control of dopaminergic, noradrenergic and serotonergic transmission in the FCX. The delineation of such interactions provides a framework for an interpretation of the influence of diverse classes of antidepressant agent upon extracellular levels of dopamine, noradrenaline and serotonin in FCX. Moreover, it also generates important insights into strategies for the potential improvement in the therapeutic profiles of antidepressant agents.

Từ khóa


Tài liệu tham khảo

10.1046/j.1460-9568.1999.00642.x

10.1007/978-1-4612-4560-5_8

10.4088/JCP.v60n0112d

10.1097/00002826-199706000-00004

10.1007/BF00169289

10.1097/00004714-199902000-00014

10.1111/j.1748-1716.1993.tb09584.x

10.1177/026988119701100208

10.1016/S0166-2236(96)10037-0

Audinot V, 1998, J Pharmacol Exp Ther, 287, 1

Audinot V, 1999, Am Soc Neurosci Abstr, 25, 584

10.1006/S1043-6618(97)90144-5

10.1038/377424a0

Balon R, 1993, J Clin Psychiatry, 54, 161

10.1176/ajp.151.5.681

10.1002/(SICI)1098-2396(199901)31:1<13::AID-SYN3>3.0.CO;2-Y

10.1016/S0014-2999(96)00999-5

10.2165/00003088-199631060-00004

10.1016/0166-4328(96)00087-3

10.1097/00001756-199810050-00022

10.1038/sj.bjp.0702074

Bel N, 1996, J Pharmacol Exp Ther, 278, 1064

Bengtsson H J, 1999, Nordic J Psychiatry, 53, 84

10.1016/0010-440X(92)90045-R

10.1016/S0924-977X(97)00418-5

10.1097/00004850-199510030-00008

10.1192/bjp.171.5.444

10.1097/00004714-199506000-00011

10.1016/0165-6147(94)90315-8

Bobker D H, 1989, J Pharmacol Exp Ther, 250, 37

10.1016/0028-3908(94)90059-0

10.1097/00004714-199812000-00005

10.1016/0028-3908(94)00145-I

10.1176/ajp.155.10.1346

10.1021/jm970030l

10.1046/j.1471-4159.1996.66062546.x

Bottcher H, 1998, Am Soc Neurosci Abstr, 24, 438.5

10.1177/026988119801200305

10.1016/S0278-5846(97)00103-6

10.1016/S0278-5846(98)00010-4

10.1021/jm00023a001

10.1002/(SICI)1099-1077(199802)13:1+<S13::AID-HUP979>3.0.CO;2-6

Burrows G D, 1998, J Clin Psychiatry, 59, 4

Cahir M, 1998, Br J Pharmacol, 125, 38P

10.1002/syn.890090404

10.1523/JNEUROSCI.14-11-06763.1994

10.1016/S0306-4522(96)00444-7

10.1016/0006-3223(95)00367-3

Carlsson A, 1975, Preand postsynaptic receptors, 49

10.4088/JCP.v60n0110

10.1016/0006-8993(92)90711-H

10.1111/j.2042-7158.1993.tb05578.x

10.1002/syn.890100308

10.1002/syn.890100106

10.1046/j.1471-4159.1995.64041585.x

Cheung N Y, 1998, Am Soc Neurosci Abstr, 24, 436.6

10.1016/0306-4522(93)90262-E

10.1097/00004714-199002000-00009

10.1007/BF01245033

Cooper B R, 1980, Drug Dev Res, 215, 127

10.1016/S0006-3223(98)00300-X

10.1523/JNEUROSCI.17-15-05738.1997

Craven R, 1997, Br J Pharmacol, 120, 261

10.1126/science.211589

10.1016/0028-3908(83)90082-5

Da-Rocha Jr M A, 1997, J Pharmacol, 11, 211

10.1523/JNEUROSCI.18-07-02729.1998

10.1192/bjp.163.6.822

10.1111/j.1476-5381.1995.tb13321.x

10.1016/S0014-2999(97)01580-X

De Battista C, 1998, Biol Psychiatry, 44, 336, 10.1016/S0006-3223(98)00163-2

De Boer T, 1996, J Pharmacol Exp Ther, 277, 852

10.1523/JNEUROSCI.18-16-06528.1998

10.1046/j.1471-4159.1999.0731033.x

10.1177/026988119601000106

10.1016/0306-4522(94)00527-C

10.1016/S0028-3908(98)00014-8

Dickinson S L, 1991, Drug News Perspect, 4, 197

10.1097/00004714-199812000-00009

10.1111/j.1476-5381.1992.tb14493.x

10.1016/0028-3908(94)90071-X

10.1016/0893-133X(95)00148-7

10.1007/BF02245186

10.1016/S0924-977X(97)00419-7

Duncan G E, 1994, J Pharmacol Exp Ther, 271, 1699

10.1007/PL00005263

10.1016/S0006-8993(97)00593-3

10.1016/0165-6147(97)81409-5

10.2165/00023210-199606020-00005

10.1523/JNEUROSCI.14-08-04839.1994

Finn M, 1998, Am Soc Neurosci Abstr, 24, 539.15

10.1016/0166-4328(96)00118-0

10.1016/0006-8993(91)90082-7

10.1021/jm00006a001

Frazer A, 1997, J Clin Psychiatry, 58, 9

10.1016/0014-2999(96)00300-7

10.1002/syn.890150109

10.1111/j.1476-5381.1995.tb15919.x

Gaster L M, 1998, Neuroscience, 84, 413, 10.1016/S0306-4522(97)00565-4

10.1002/ddr.430350406

10.1016/S0021-9258(17)33961-3

Glassman A H, 1998, Clin Psychiatry, 59, 13

10.1111/j.2042-7158.1993.tb05691.x

10.1016/S0028-3908(98)00188-9

Gobert A, 1999, Neuropsychopharmacology, 21, 268, 10.1016/S0893-133X(99)00035-4

Gobert A, 1995, J Pharmacol Exp Ther, 273, 1032

Gobert A, 1995, J Pharmacol Exp Ther, 275, 899

10.1046/j.1471-4159.1996.66052209.x

10.1046/j.1471-4159.1997.69062616.x

10.1046/j.1471-4159.1997.68031326.x

10.1046/j.1471-4159.1997.68031159.x

10.1016/S0306-4522(97)00565-4

Gobert A, 1999, Am Soc Neurosci Abstr, 25, 533.11

Gobert A, 1999, Neuroscience, 93, 1251, 10.1016/S0306-4522(99)00211-0

Gobert A, Neuropharmacology, 39

Gobert A, Synapse, 36

10.1007/BF02246213

10.1093/schbul/23.3.437

10.1177/0269881198012003041

10.1046/j.1460-9568.1998.00375.x

10.1177/0269881198012003021

10.1177/0269881198012003031

10.1177/026988119701100204

10.1136/bmj.1.5798.463

10.1007/s002130050787

10.1007/BF01244934

10.1046/j.1471-4159.1995.65010111.x

10.1016/S0028-3908(97)00034-8

10.1007/BF01271201

10.1038/sj.bjp.0702028

10.1016/S0021-9258(17)37256-3

10.1016/S0893-133X(98)00066-9

Haddjeri N, 1996, J Pharmacol Exp Ther, 277, 861

10.1523/JNEUROSCI.18-23-10150.1998

10.1038/sj.bjp.0701196

10.1111/j.1527-3458.1997.tb00315.x

Heisler L K, 1998, Am Soc Neurosci Abstr, 24, 238.10

10.1073/pnas.95.25.15049

10.1074/jbc.271.48.30554

10.1016/0006-8993(94)91121-5

10.1016/S0278-5846(98)00042-6

10.1016/S0014-2999(98)00579-2

Hieble J P, 1996, Prog Drug Res, 47, 1906

10.1517/13543784.6.4.367

Hjorth S, 1998, Am Soc Neurosci Abstr, 24, 438.13

10.1016/0024-3205(91)90216-X

Hjorth S, 1993, J Pharmacol Exp Ther, 265, 707

10.1016/0028-3908(95)00038-8

10.1007/BF01276574

10.1001/archpsyc.1995.03950130029004

10.1016/S0014-2999(96)00715-7

10.1038/sj.bjp.0701947

10.1038/sj.bjp.0701520

10.1097/00004850-199403001-00004

10.1016/0014-2999(95)00264-L

10.1016/S0014-2999(98)00308-2

10.1016/S0028-3908(97)00060-9

Iyer R N, 1996, J Pharmacol Exp Ther, 277, 40

10.1016/0163-7258(94)90041-8

10.1016/0014-2999(93)90453-O

10.1016/0278-5846(94)90013-2

10.1016/S0924-977X(97)00055-2

10.1523/JNEUROSCI.12-05-02000.1992

Jonas J M, 1993, J Clin Psychiatry, 54, 25

10.1002/syn.890180404

Katz R J, 1994, J Clin Psychiatry, 55, 314

Kelland M D, 1996, The modulation of dopaminergic neurotransmission by other neurotransmitters, 87

10.1523/JNEUROSCI.18-09-03470.1998

10.1111/j.1476-5381.1996.tb15208.x

10.1016/S0028-3908(96)00171-2

10.1016/S0028-3908(97)00038-5

10.1016/S0006-3223(98)00210-8

Kessler R M, 1998, Am Soc Neurosci Abstr, 24, 340

10.1002/(SICI)1096-9861(19981221)402:3<353::AID-CNE5>3.0.CO;2-4

10.1192/bjp.162.6.744

King J A, 1998, Am Soc Neurosci Abstr, 24, 484.18

10.1016/0006-8993(94)01447-P

Klysner R, 1991, Advances in neuropsychiatry and psychopharmacology: refractory depression, 113

10.1523/JNEUROSCI.18-06-02231.1998

10.1146/annurev.med.46.1.113

10.1016/0014-2999(95)00069-W

10.1097/00006231-199504000-00159

Kuroki T, 1999, J Pharmacol Exp Ther, 288, 774

10.1073/pnas.94.18.9950

10.1055/s-2007-1014403

10.1152/physrev.1991.71.1.155

10.1016/S0006-8993(98)00266-2

10.1016/S0306-4522(97)00578-2

10.1016/0014-2999(95)00106-U

10.1002/(SICI)1098-2396(199810)30:2<172::AID-SYN7>3.0.CO;2-9

10.1016/0014-2999(94)90012-4

Lejeune F, 1997, Am Soc Neurosci Abstr, 23, 386

Lejeune F, 1997, J Pharmacol Exp Ther, 280, 1241

Lejeune F, 1998, Am Soc Neurosci Abstr, 24, 341

Leonard B E, 1997, J Psychopharmacol, 11, S39

10.1016/S0006-8993(98)00529-0

10.1016/S0006-8993(98)00146-2

10.1016/0278-5846(89)90123-1

10.1016/0149-7634(94)90039-6

10.1111/j.1476-5381.1993.tb12859.x

Maes M, 1995, Psychopharmacology: the fourth generation in progress, 933

10.1016/S0006-3223(98)00272-8

Malmberg A, 1998, J Pharmacol Exp Ther, 285, 119

Martin J R, 1998, J Pharmacol Exp Ther, 286, 913

10.1046/j.1471-4159.1998.71020790.x

Matos F F, Proceedings of the 6th International Conference on in vivoMethods, 207

10.1007/BF00176618

10.1016/0014-2999(95)00333-G

10.1097/00001756-199703030-00048

McAskill R, 1998, Br J Pharmacol, 173, 203

10.1001/archpsyc.1994.03950040046006

10.1097/00001504-199701000-00007

10.1073/pnas.91.17.8297

Meller E, 1990, Mol Pharmacol, 37, 231

Meltzer H Y, 1995, Psychopharmacology: the fourth generation in progress, 1277

10.1007/BF02244995

10.1192/S0007125000075292

10.1016/S0306-4522(99)00213-4

Mercuri N B, 1997, Neuroscience, 79, 323, 10.1016/S0306-4522(97)00135-8

10.1021/jm960723m

10.1007/BF02245590

10.1007/s007020050097

10.1016/S0028-3908(99)00012-X

10.1016/S0014-2999(97)00050-2

Millan M J, 1992, J Pharmacol Exp Ther, 262, 451

Millan M J, 1994, J Pharmacol Exp Ther, 270, 958

Millan M J, 1997, J Pharmacol Exp Ther, 282, 148

Millan M J, 1997, J Pharmacol Exp Ther, 282, 132

10.1016/S0014-2999(97)01445-3

10.1016/S0028-3908(98)00078-1

Millan M J, 1998, J Pharmacol Exp Ther, 286, 1341

Millan M J, 1998, J Pharmacol Exp Ther, 287, 167

Millan M J, 1999, Am Soc Neurosci Abstr, 25, 588.2

Millan M J, 1999, J Pharmacol Exp Ther, 288, 1002

Millan M J, 1999, Neuropsychopharmacology, 21, 61S

10.1016/S0014-2999(98)00802-4

Millan M J, 2000, Synapse, 35, 72, 10.1002/(SICI)1098-2396(200002)35:2<79::AID-SYN1>3.0.CO;2-X

Millan M J, J Pharmacol Exp Ther

Millan M J, Eur J Neurosci, 12

10.1097/00001504-199703000-00006

10.1002/med.2610060204

10.1007/BF00167444

Mongeau R, 1994, J Pharmacol Exp Ther, 269, 1152

10.1016/0014-2999(94)90272-0

10.1037/0735-7044.109.4.681

10.1016/0306-4522(93)90241-7

10.1016/S0924-977X(98)00015-7

Moser P C, 1996, Am Soc Neurosci Abstr, 22, 76

10.1097/00004850-199809000-00005

Murphy D L, 1998, J Clin Psychiatry, 59, 4

10.1007/BF00171039

Nelson J C, 1987, Treat Resist Depress, 7, 131

10.1002/(SICI)1520-6394(1996)4:4<169::AID-DA3>3.0.CO;2-A

10.1016/0165-1781(90)90093-K

Newman-Tancredi A, 1996, Brain Res Bull, 41, 93

10.1016/S0893-133X(97)00169-3

Newman-Tancredi A, 1999, Mol Pharmacol, 55, 564

10.1046/j.1471-4159.1997.69031031.x

10.1016/0306-4522(93)90148-9

10.1097/00001756-199502000-00041

10.1097/00001756-199810260-00032

O'Donnell J, 1993, Res Commun Chem Pathol Pharmacol, 80, 113

10.1016/0091-3057(95)02047-0

10.1016/0024-3205(91)90356-G

10.1177/026988119400800111

10.1097/00004850-199807006-00003

10.1001/archpsyc.1989.01810100100021

10.1038/350350a0

10.1007/BF02245008

10.1097/00001756-199604260-00003

10.1007/BF02246453

10.1152/jn.1989.61.4.719

10.1016/0006-8993(85)90856-X

Pehek E A, 1998, Am Soc Neurosci Abstr, 24, 48

10.1016/0278-5846(96)00076-0

10.1016/0006-8993(94)90495-2

10.1016/0006-3223(95)00049-7

10.1002/med.2610130304

10.1016/0893-133X(95)00109-Q

10.1002/(SICI)1098-2396(199601)22:1<54::AID-SYN6>3.0.CO;2-H

10.1016/0006-3223(93)90145-4

10.1016/0169-328X(94)90223-2

10.1046/j.1471-4159.1994.63010195.x

10.1007/PL00005056

10.1111/j.1476-5381.1995.tb16684.x

Prisco S, 1994, J Pharmacol Exp Ther, 271, 83

Quested D J, 1997, J Psychopharmacol, 11, A37

10.1073/pnas.95.24.14476

10.1016/S0014-2999(97)00115-5

10.1007/s002130050663

10.1016/S0014-2999(96)00772-8

10.1016/0014-2999(94)90774-9

10.1007/s002130050555

Renouard A, 1994, J Pharmacol Exp Ther, 270, 946

10.1016/0169-328X(95)00112-6

10.1016/0306-4522(95)00283-O

10.1192/bjp.164.6.802

Riva M, 1989, J Drug Dev, 1, 243

10.1016/0014-2999(94)90429-4

Rivet J-M, Proceedings of the 7th International Conference on in vivoMethods, 103

Rivet J-M, 1998, Am Soc Neurosci Abstr, 24, 440.9

10.1016/S0028-3908(97)00026-9

10.1016/S0361-9230(98)00126-9

10.1046/j.1471-4159.1996.67052204.x

10.1016/S0014-2999(97)81951-6

10.1097/00004714-199902000-00013

10.1002/(SICI)1096-9861(19960812)372:1<135::AID-CNE9>3.0.CO;2-4

10.1016/0014-2999(89)90214-8

Rothschild A J, 1993, J Clin Psychiatry, 54, 338

10.1016/0014-2999(94)90300-X

10.1016/0301-0082(93)90023-L

Sachs G S, 1986, J Clin Psychiatry, 47, 508

10.1016/S0306-4522(98)00275-9

10.1254/jjp.70.203

10.1124/mol.51.1.36

Sambunaris A, 1997, J Clin Psychiatry, 58, 40

10.1007/s002130050747

10.1016/S0306-4522(98)00256-5

Schatzberg A F, 1998, J Clin Psychiatry, 59, 15, 10.4088/JCP.v59n1007b

10.1007/PL00005057

10.1016/0014-2999(94)00698-7

10.1046/j.1471-4159.1994.62041382.x

10.1016/0278-5846(93)90034-P

10.1016/0014-2999(94)90643-2

Schreiber R, 1995, J Pharmacol Exp Ther, 273, 101

10.1517/13543784.6.1.65

10.1523/JNEUROSCI.14-01-00088.1994

10.1111/j.1476-5381.1989.tb11815.x

10.1038/sj.bjp.0701235

10.1124/mol.52.6.1056

10.1016/0006-3223(92)90279-9

10.1358/dof.1998.023.02.445830

10.1093/schbul/17.1.75

10.1001/archpsyc.1994.03950020033003

10.1016/0028-3908(94)00167-Q

10.1176/ajp.155.10.1339

10.1016/S0006-3223(96)00006-6

10.1016/S0165-6147(00)89044-6

Sorensen S M, 1993, J Pharmacol Exp Ther, 266, 684

Sperling W L, 1997, Drugs Today, 33, 95

Srisurapanont M, 1997, J Med Assoc Thai, 80, 183

10.1523/JNEUROSCI.16-23-07566.1996

10.1152/physrev.1989.69.3.864

10.1016/0028-3908(94)90069-8

10.1016/S0006-3223(98)00084-5

10.1016/S0006-8993(97)01078-0

10.1016/0006-8993(75)90276-0

10.1097/00004714-199502001-00003

10.1002/(SICI)1099-1077(199802)13:1+<S3::AID-HUP981>3.0.CO;2-O

10.1007/BF02244785

10.1007/BF02246048

Tang L, 1994, J Pharmacol Exp Ther, 270, 475

10.1007/BF00165728

10.1523/JNEUROSCI.17-07-02519.1997

Thase M E, 1995, Psychopharmacology, 92, 1081

Thorn L, 1997, Br J Pharmacol, 120, 257P

Tian W N, 1993, Mol Pharmacol, 45, 524

Tingley F D, 1998, Am Soc Neurosci Abstr, 24, 438

10.1097/00004850-199703000-00003

10.1007/BF00168534

10.1007/BF00173016

10.1007/BF00178202

10.1046/j.1471-4159.1997.69052019.x

10.1016/S0014-2999(98)00590-1

10.1016/0197-4580(94)90053-1

10.1111/j.1476-5381.1993.tb13623.x

10.1523/JNEUROSCI.16-08-02605.1996

10.1016/S0014-2999(98)00711-0

Wiech N L, 1980, Commun Psychopharmacol, 4, 95

Willins D L, 1997, J Pharmacol Exp Ther, 282, 699

10.1016/S0006-8993(97)01267-5

Willner P, 1995, Psychopharmacology: the fourth generation in progress, 921

10.1055/s-2007-979589

Wurtman R J, 1998, Am Soc Neurosci Abstr, 24, 541

10.1016/0014-2999(95)00582-X

10.1097/00004714-199712000-00002

10.1097/00004714-199812000-00004

10.1016/0169-328X(91)90064-5

Thông tin
Thông tin xuất bản

Journal of Psychopharmacology

Tập 14 Số 2

114-138

Thông tin tác giả